Ocugen (OCGN) Valuation Check After Encouraging Phase 2 ArMaDa Results For OCU410 [Yahoo! Finance]
Ocugen, Inc. (OCGN)
Company Research
Source: Yahoo! Finance
Ocugen (OCGN) has drawn fresh investor attention after releasing full Phase 2 ArMaDa data for OCU410, showing a 46% reduction in macular lesion growth at 12 months and no therapy related serious adverse events. See our latest analysis for Ocugen. Despite the recent ArMaDa update, Ocugen's 1 day share price return of 5.08% and 7 day return of 13.85% sit against a 21.74% year to date gain and a very large 1 year total shareholder return. This hints that enthusiasm around its gene therapy pipeline has been tempered in the short term but remains strong when viewed over the past year. If this kind of biotech momentum has your attention, it could be a good moment to scan other opportunities in vision and treatment focused healthcare, starting with 35 healthcare AI stocks So with Ocugen still loss making on modest revenue, yet carrying very large 1 year returns and analyst targets well above the recent US$1.68 share price, are you looking at an undervalued gene therapy play, or has
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Ocugen to Present at April 2026 Investor and Industry ConferencesGlobeNewswire
- OCU410's Phase 2 Gene-Agnostic Results in Dry AMD Might Change The Case For Investing In Ocugen (OCGN) [Yahoo! Finance]Yahoo! Finance
- Evaluating Ocugen (OCGN) After Recent Share Price Swings And Gene Therapy Progress [Yahoo! Finance]Yahoo! Finance
- Ocugen (OCGN) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OCGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sell"MarketBeat
- Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease [Yahoo! Finance]Yahoo! Finance
OCGN
Earnings
- 3/4/26 - In-Line
OCGN
Sec Filings
- 4/20/26 - Form PRER14A
- 4/17/26 - Form PRE
- 4/14/26 - Form SCHEDULE
- OCGN's page on the SEC website